Role of a gene in spread of hepatitis C-related liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how a certain RNA molecule (called LINC01134) affects the spread of liver cancer in people with hepatitis C. It may help doctors understand why cancer spreads and could lead to better treatments. You would have a blood or tissue sample taken, but there is no new drug or intervention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have hepatitis C infection (confirmed by blood tests for more than 6 months).
- Must have liver cirrhosis (hardening of the liver) diagnosed by doctors.
- Must have liver cancer (hepatocellular carcinoma) confirmed by special imaging scans (CT scan or similar).
- Must not have hepatitis B infection (another type of liver virus).
- Must not have other causes of liver damage (like heavy alcohol use, autoimmune liver disease, or fatty liver disease).
- Must not have had any previous treatment for liver cancer or other types of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for people with or without liver cancer to test a new way to find liver cancer early using blood or tissue samples. It aims to help catch the disease sooner.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
This study looks at how liver cancer (hepatocellular carcinoma) progresses and responds in people who have a history of viral hepatitis (hepatitis B or C) and also have a fatty liver condition (MASLD). It aims to understand whether having both conditions changes survival compared with having only viral hepatitis. If you have liver cancer and either viral hepatitis or both conditions, this study could help tailor your care.
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.